Logo image
Use of ATP analogs to inhibit HIV-1 transcription
Journal article   Peer reviewed

Use of ATP analogs to inhibit HIV-1 transcription

Aarthi Narayanan, Gavin Sampey, Rachel Van Duyne, Irene Guendel, Kylene Kehn-Hall, Jessica Roman, Robert Currer, Hervé Galons, Nassima Oumata, Benoît Joseph, …
Virology (New York, N.Y.), v 432(1), pp 219-231
10 Oct 2012
PMID: 22771113
url
https://doi.org/10.1016/j.virol.2012.06.007View
Published, Version of Record (VoR) Restricted

Abstract

ATP analog cdk9 Cyclin T1 HIV-1 Tat Transcription
Human immunodeficiency virus type 1 (HIV-1) is the etiological agent of AIDS. Chronic persistent infection is an important reason for the presence of “latent cell populations” even after Anti-Retroviral Therapy (ART). We have analyzed the effect of ATP analogs in inhibiting cdk9/T1 complex in infected cells. A third generation drug named CR8#13 is an effective inhibitor of Tat activated transcription. Following drug treatment, we observed a decreased loading of cdk9 onto the HIV-1 DNA. We found multiple novel cdk9/T1 complexes present in infected and uninfected cells with one complex being unique to infected cells. This complex is sensitive to CR8#13 in kinase assays. Treatment of PBMC with CR8#13 does not kill infected cells as compared to Flavopiridol. Interestingly, there is a difference in sensitivity of various clades to these analogs. Collectively, these results point to targeting novel complexes for inhibition of cellular proteins that are unique to infected cells.

Metrics

6 Record Views
24 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Virology
Logo image